`

Annexon Biosciences

Biotechnology Research

Specialities :
Neurodegeneration
Autoimmune
And ophthalmology
revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$125.0M
size-icon Size
51 - 200

Frequently Asked Questions About Annexon Biosciences

What does Annexon biosciences do?+

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The companys pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is...

What are Annexon biosciences's specialties? +

Neurodegeneration,autoimmune,and ophthalmology

What is Annexon biosciences's industry? +

Annexon biosciences operates in the Biotechnology research industry.

What is Annexon biosciences's revenue? +

Annexon biosciences's revenue is 11m - 100m

What is Annexon biosciences's company size? +

Annexon biosciences has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.